389 related articles for article (PubMed ID: 25649370)
21. Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors.
Morgenstern DA; Marzouki M; Bartels U; Irwin MS; Sholler GL; Gammon J; Yankanah R; Wu B; Samson Y; Baruchel S
Pediatr Blood Cancer; 2014 Jan; 61(1):128-33. PubMed ID: 23956145
[TBL] [Abstract][Full Text] [Related]
22. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
23. A Phase I/II Investigation of Safety and Efficacy of Nivolumab and
Gordon EM; Angel NL; Omelchenko N; Chua-Alcala VS; Moradkhani A; Quon D; Wong S
Anticancer Res; 2023 May; 43(5):1993-2002. PubMed ID: 37097693
[TBL] [Abstract][Full Text] [Related]
24. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L
J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840
[TBL] [Abstract][Full Text] [Related]
25. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
Chow LQ; Jonker DI; Dy GK; Nicholas G; Fortin C; Patricia D; Adjei AA; Belani CP; Gupta A; Park JS; Zhang S; Sbar EI; Laurie SA
Cancer Chemother Pharmacol; 2013 May; 71(5):1273-85. PubMed ID: 23468081
[TBL] [Abstract][Full Text] [Related]
26. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.
Ko YJ; Canil CM; Mukherjee SD; Winquist E; Elser C; Eisen A; Reaume MN; Zhang L; Sridhar SS
Lancet Oncol; 2013 Jul; 14(8):769-76. PubMed ID: 23706985
[TBL] [Abstract][Full Text] [Related]
27. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
Khawaja MR; Nick AM; Madhusudanannair V; Fu S; Hong D; McQuinn LM; Ng CS; Piha-Paul SA; Janku F; Subbiah V; Tsimberidou A; Karp D; Meric-Bernstam F; Lu KH; Naing A
Cancer Chemother Pharmacol; 2016 May; 77(5):973-7. PubMed ID: 27014780
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors.
Semrad TJ; Eddings C; Dutia MP; Christensen S; Lara PN
Anticancer Drugs; 2013 Jul; 24(6):636-40. PubMed ID: 23698253
[TBL] [Abstract][Full Text] [Related]
29. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.
Gonzalez-Angulo AM; Meric-Bernstam F; Chawla S; Falchook G; Hong D; Akcakanat A; Chen H; Naing A; Fu S; Wheler J; Moulder S; Helgason T; Li S; Elias I; Desai N; Kurzrock R
Clin Cancer Res; 2013 Oct; 19(19):5474-84. PubMed ID: 24089446
[TBL] [Abstract][Full Text] [Related]
30. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Ott PA; Chang J; Madden K; Kannan R; Muren C; Escano C; Cheng X; Shao Y; Mendoza S; Gandhi A; Liebes L; Pavlick AC
Cancer Chemother Pharmacol; 2013 Jan; 71(1):183-91. PubMed ID: 23064957
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Khuri FR; Glisson BS; Kim ES; Statkevich P; Thall PF; Meyers ML; Herbst RS; Munden RF; Tendler C; Zhu Y; Bangert S; Thompson E; Lu C; Wang XM; Shin DM; Kies MS; Papadimitrakopoulou V; Fossella FV; Kirschmeier P; Bishop WR; Hong WK
Clin Cancer Res; 2004 May; 10(9):2968-76. PubMed ID: 15131032
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
[TBL] [Abstract][Full Text] [Related]
33. Phase I and pharmacokinetic study of polymeric micelle‑formulated paclitaxel in adult Chinese patients with advanced solid tumors.
Lv F; Cao J; Zhang J; Qian J; Peng W; Sun S; Li W; Zhang W; Guo W; Li J
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1173-9. PubMed ID: 24658629
[TBL] [Abstract][Full Text] [Related]
34. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
[TBL] [Abstract][Full Text] [Related]
35. A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.
Choo SP; Chowbay B; Ng QS; Thng CH; Lim C; Hartono S; Koh TS; Huynh H; Poon D; Ang MK; Chang S; Toh HC
Eur J Cancer; 2013 Mar; 49(5):999-1008. PubMed ID: 23265712
[TBL] [Abstract][Full Text] [Related]
36. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
Robidoux A; Buzdar AU; Quinaux E; Jacobs S; Rastogi P; Fourchotte V; Younan RJ; Pajon ER; Shalaby IA; Desai AM; Fehrenbacher L; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2010 Feb; 10(1):81-6. PubMed ID: 20133263
[TBL] [Abstract][Full Text] [Related]
37. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.
Boers-Sonderen MJ; de Geus-Oei LF; Desar IM; van der Graaf WT; Oyen WJ; Ottevanger PB; van Herpen CM
Target Oncol; 2014 Dec; 9(4):339-47. PubMed ID: 24577626
[TBL] [Abstract][Full Text] [Related]
38. Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer.
Acevedo-Gadea C; Santin AD; Higgins SA; Urva S; Ratner E; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Abu-Khalaf MM
Int J Gynecol Cancer; 2014 Mar; 24(3):528-33. PubMed ID: 24557436
[TBL] [Abstract][Full Text] [Related]
39. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.
Campone M; Levy V; Bourbouloux E; Berton Rigaud D; Bootle D; Dutreix C; Zoellner U; Shand N; Calvo F; Raymond E
Br J Cancer; 2009 Jan; 100(2):315-21. PubMed ID: 19127256
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
Amato RJ; Sarao H
Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
